Century Therapeutics Inc
IPSC
View Detailed Chart
0.900USD
+0.137+17.89%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
77.87MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+17.89%
5 Days
+61.38%
1 Month
+83.67%
6 Months
+54.67%
Year to Date
-10.89%
1 Year
-18.18%
View Detailed Chart
TradingKey Stock Score of Century Therapeutics Inc
Currency: USD Updated: 2025-12-19Key Insights
Century Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 61/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Century Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
5
analysts
Buy
Current Rating
4.000
Target Price
+601.75%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Century Therapeutics Inc Highlights
StrengthsRisks
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.74% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.59M.
Undervalued
The company’s latest PE is -2.87, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 36.05M shares, decreasing 28.32% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 2.59M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.49.
Century Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Century Therapeutics Inc Info
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
Ticker SymbolIPSC
CompanyCentury Therapeutics Inc
CEOPfeiffenberger (Brent)
Websitehttps://www.centurytx.com/
FAQs
What is the current price of Century Therapeutics Inc (IPSC)?
The current price of Century Therapeutics Inc (IPSC) is 0.900.
What is the symbol of Century Therapeutics Inc?
The ticker symbol of Century Therapeutics Inc is IPSC.
What is the 52-week high of Century Therapeutics Inc?
The 52-week high of Century Therapeutics Inc is 1.185.
What is the 52-week low of Century Therapeutics Inc?
The 52-week low of Century Therapeutics Inc is 0.342.
What is the market capitalization of Century Therapeutics Inc?
The market capitalization of Century Therapeutics Inc is 77.87M.
What is the net income of Century Therapeutics Inc?
The net income of Century Therapeutics Inc is -126.57M.
Is Century Therapeutics Inc (IPSC) currently rated as Buy, Hold, or Sell?
According to analysts, Century Therapeutics Inc (IPSC) has an overall rating of Buy, with a price target of 4.000.
What is the Earnings Per Share (EPS TTM) of Century Therapeutics Inc (IPSC)?
The Earnings Per Share (EPS TTM) of Century Therapeutics Inc (IPSC) is -0.314.
Related Instruments
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%Popular Symbols
